X4 Pharmaceuticals (XFOR) Assets (2017 - 2025)

X4 Pharmaceuticals has reported Assets for 9 years, with the latest figure at $290.5 million in Q4 2025.

• For the quarter ending Q4 2025, Assets rose 98.34% year-over-year to $290.5 million; the trailing twelve-month figure through Dec 2025 stood at $290.5 million (up 98.34% YoY), and the FY2025 full-year result was $290.5 million, up 98.34% from the prior year.
• Assets for Q4 2025 stood at $290.5 million, up from $163.6 million in the prior quarter.
• The five-year high for Assets was $290.5 million in Q4 2025, with the low at $81.0 million in Q2 2022.
• Historically, Assets has averaged $147.2 million across 5 years, with a median of $144.1 million in 2021.
• Annual changes were most pronounced in 2023 — Assets surged 114.02% — and 2025, when it plunged 50.07%.
• X4 Pharmaceuticals' Assets stood at $117.2 million in 2021, then soared by 32.78% to $155.6 million in 2022, then retreated by 5.35% to $147.3 million in 2023, then retreated by 0.55% to $146.4 million in 2024, then jumped by 98.34% to $290.5 million in 2025.
• The last three Assets figures came in at $290.5 million (Q4 2025), $163.6 million (Q3 2025), and $105.2 million (Q2 2025), per Business Quant data.